Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2026)

Royalty Pharma has reported Interest & Investment Income for 8 years, with the latest figure at $6.2 million in Q1 2026.

• Quarterly Interest & Investment Income fell 44.83% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.5 million (down 44.29% YoY) and the FY2025 annual result came in at $33.6 million, down 29.05% from the prior year.
• Interest & Investment Income fell to $6.2 million in Q1 2026 per RPRX's latest filing, from $7.1 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $43.9 million in Q4 2022 and troughed at $6.2 million in Q1 2026.
• A 5-year average of $14.0 million and a median of $10.9 million in 2022 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income jumped 312.19% in 2022, then tumbled 85.18% in 2023.
• Over 5 years, Interest & Investment Income stood at $43.9 million in 2022, then sank by 85.18% to $6.5 million in 2023, then jumped by 39.03% to $9.0 million in 2024, then dropped by 21.76% to $7.1 million in 2025, then declined by 11.91% to $6.2 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $6.2 million, $7.1 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.